Ensign Peak Advisors Inc Decreases Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Ensign Peak Advisors Inc lowered its stake in Blueprint Medicines Co. (NASDAQ:BPMC) by 4.1% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 306,316 shares of the biotechnology company’s stock after selling 13,212 shares during the quarter. Ensign Peak Advisors Inc owned about 0.49% of Blueprint Medicines worth $33,015,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the stock. Amalgamated Bank boosted its position in Blueprint Medicines by 5.3% in the 2nd quarter. Amalgamated Bank now owns 2,154 shares of the biotechnology company’s stock valued at $232,000 after buying an additional 109 shares during the last quarter. Van ECK Associates Corp grew its stake in Blueprint Medicines by 13.3% during the 2nd quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 131 shares in the last quarter. EFG Asset Management North America Corp. increased its holdings in Blueprint Medicines by 0.5% during the 2nd quarter. EFG Asset Management North America Corp. now owns 27,884 shares of the biotechnology company’s stock worth $3,008,000 after purchasing an additional 132 shares during the last quarter. US Bancorp DE raised its position in shares of Blueprint Medicines by 5.2% in the 1st quarter. US Bancorp DE now owns 3,724 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 183 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Blueprint Medicines by 1.7% during the 4th quarter. Principal Financial Group Inc. now owns 14,510 shares of the biotechnology company’s stock valued at $1,338,000 after buying an additional 247 shares during the last quarter.

Blueprint Medicines Trading Up 0.8 %

Shares of NASDAQ:BPMC opened at $91.68 on Monday. Blueprint Medicines Co. has a fifty-two week low of $43.89 and a fifty-two week high of $121.90. The company has a quick ratio of 3.65, a current ratio of 3.71 and a debt-to-equity ratio of 1.06. The company has a market cap of $5.74 billion, a PE ratio of -19.06 and a beta of 0.58. The company’s 50-day moving average price is $97.76 and its 200 day moving average price is $99.09.

Blueprint Medicines (NASDAQ:BPMC) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.29) by $0.49. Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%. The business had revenue of $138.20 million during the quarter, compared to the consensus estimate of $104.02 million. During the same period in the previous year, the firm posted ($2.19) earnings per share. The business’s revenue was up 139.9% on a year-over-year basis. Sell-side analysts anticipate that Blueprint Medicines Co. will post -3.99 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Debra Durso-Bumpus sold 333 shares of the firm’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $111.15, for a total transaction of $37,012.95. Following the transaction, the insider now directly owns 43,763 shares of the company’s stock, valued at $4,864,257.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Blueprint Medicines news, insider Philina Lee sold 41,913 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $93.19, for a total transaction of $3,905,872.47. Following the completion of the transaction, the insider now directly owns 34,729 shares of the company’s stock, valued at approximately $3,236,395.51. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Debra Durso-Bumpus sold 333 shares of the business’s stock in a transaction on Friday, June 28th. The stock was sold at an average price of $111.15, for a total value of $37,012.95. Following the completion of the sale, the insider now directly owns 43,763 shares in the company, valued at approximately $4,864,257.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 54,913 shares of company stock worth $5,352,249. 4.21% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. JMP Securities restated a “market outperform” rating and issued a $125.00 price target on shares of Blueprint Medicines in a research note on Friday, June 7th. Morgan Stanley upped their target price on shares of Blueprint Medicines from $110.00 to $115.00 and gave the company an “equal weight” rating in a research note on Friday, July 12th. Guggenheim increased their price target on shares of Blueprint Medicines from $130.00 to $138.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Baird R W raised Blueprint Medicines to a “strong-buy” rating in a report on Friday, August 2nd. Finally, Robert W. Baird increased their target price on Blueprint Medicines from $112.00 to $127.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Blueprint Medicines currently has an average rating of “Moderate Buy” and a consensus target price of $120.00.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.